Our laboratory continues to be actively involved in the development of new biomarkers for prenatal diagnosis using maternal blood and amniotic fluid. We have also developed a mouse model that demonstrates that cell-free fetal (cff) DNA is detectable in the pregnant maternal mouse.
demonstrates that cell-free fetal (cff) DNA is detectable in the pregnant maternal mouse.
In human maternal plasma and serum we have analyzed factors that will be important in the clinical interpretation of cff-DNA levels, such as maternal weight, race, parity, smoking history, and type of conception (natural or assisted).
We have also analyzed the relationship between placental volume, using 3-dimensionsal ultrasound examination and cff-DNA levels. Surprisingly, there is no association between these values. Finally, we are using specific disease models (such as congenital diaphragmatic hernia and twin to twin transfusion) to understand the effects of gestational age and specific pathology on fetal gene expression by analyzing cell-free mRNA levels in maternal plasma.
In the amniotic fluid we have focused on improvements in recovery of cell-free fetal DNA and RNA. By optimizing recovery we have made some interesting observations about differences in fetal DNA between blood and amniotic fluid. In addition we have successfully hybridized cff-DNA in amniotic fluid to DNA microarrays, permitting assessment of fetal molecular karyotype. We also have preliminary data on fetal gene expression in amniotic fluid.
Finally, we remain actively involved in promoting noninvasive prenatal testing in the US, such as encouraging the use of fetal DNA for fetal Rhesus D assessment. On the other hand, we are cautious and concerned about the availability of "at-home" kits for gender detection. The discovery of fetal DNA in maternal plasma has opened up new possibilities for noninvasive prenatal diagnosis and monitoring. Quantitative aberrations in circulating fetal DNA have been observed in a number of pregnancy-associated disorders. The use of genetic markers for fetal DNA detection is complicated by the fact that no single genetic marker can differentiate fetal from maternal DNA in all fetus-mother pairs. Over the last few years our group has been exploring the possibility of using differential patterns of DNA methylation between maternal and fetal tissues for the development of universal fetal DNA markers. The fetal tissue that we have focused on is the placenta, in which many lines of evidence have indicated to be a predominant source of circulating fetal DNA. For maternal tissues, we have focused on maternal blood cells, following previous work in our group which indicated that hematopoietic cells are the predominant source of plasma DNA in a bone marrow transplant model. By using bisulphite sequencing of placental and maternal blood cell DNA samples, we have identified differential patterns of DNA methylation in the maspin gene in placental (hypomethylated) and maternal blood cells (hypermethylated). With the use of real-time methylation-specific PCR, the placental, hypomethylated, form of the maspin gene can be detected in maternal plasma in all three trimesters of gestation. Furthermore, such sequences are cleared very rapidly following delivery of the fetus. We believe that hypomethylated maspin is the first universal marker for fetal DNA in maternal plasma. The presence of cell free circulatory nucleic acids was first reported almost 60 years ago by Mandel and Métais, however, it is only in recent years that this phenomenon has gained the interest of the wider scientific community, especially in oncology and prenatal medicine. Prompted by observations made in cancer patients by Anker and Stroun that tumour-derived DNA was detectable in plasma samples, Lo and colleagues in 1997 detected cell free fetal DNA in the plasma of pregnant women, thereby opening a new avenue for the noninvasive assessment of fetal genetic traits. In those instances where the fetal loci being interrogated are completely absent from the maternal genome, such as the fetal RhD gene in Rhd pregnant women, this approach has been found to be so reliable that it is already being used clinically in several European centres e.g. Amsterdam, Bristol, Paris.
The detection of other fetal genetic loci which differ slightly from maternal ones has proven to be more problematic, as the vast majority (>95%) of circulating cell free DNA in maternal plasma is of maternal origin. Therefore, the detection of fetal loci involving point mutations, which are of greatest interest for single gene disorders, has been restricted to single case reports.
In this regard we and others have recently made the observation that circulatory fetal DNA sequences are generally smaller than comparable maternal ones. We furthermore showed that by selecting sequences with a small size a selective enrichment of fetal DNA sequences can be attained. By using this approach we have shown that otherwise masked fetal loci, such as STRs or point mutations, can be reliably detected.
In a separate development, Lo and colleagues has shown that fetal SNPs could be reliably detected using MALDI-TOF. We are now testing this approach in combination with that of size-fractionation, by which means we hope to be able to detect both paternal and maternal fetal SNP loci. Such a development would permit a clear non-invasive prenatal diagnosis Background: The rapid clearance of fetal nucleic acids from the maternal circulation following delivery presents an opportunity to identify unique, gender-independent markers. We used expression microarrays to study differences between peripartum women and their newborns.
Methods: Paired sample sets were obtained from pregnant women immediately prior to term delivery and 24 hours postpartum, along with their newborn's umbilical cord blood. Controls were nonpregnant women. Total RNA was extracted from whole blood samples in accordance with the PAXgeneTM blood RNA kit protocol. Successful RNA extraction was confirmed using real-time RT -PCR for the housekeeping gene GAPDH.
RNA was amplified in accordance with the AffymetrixTM One-step Amplification Protocol. Samples were hybridised to the AffymetrixTM HGU133a microarrays, scanned with the GeneArray Scanner and analysed using the GeneChip Microarray Suite 5.0 (AffymetrixTM).
Results: We successfully isolated, amplified and hybridised mRNA from maternal and newborn whole blood to oligonucleotides microarrays. Umbilical cord blood consistently had greater amounts of extracted and amplified mRNA. Comparative analysis between genes expressed in both the antepartum and the corresponding umbilical samples, but absent in both the postpartum and the control samples, identified a subset of genes that are presumable fetal in nature. In order to provide a non-invasive prenatal diagnosis of α othalassemia (SEA deletion), we have developed a real-time quantitative semi-nested PCR method for identifying the fetal α othalassemia in maternal plasma. Analysis was performed on 13 pregnant women during 8-20 weeks of gestation who carried fetuses with normal (2/13), α o -thalassemia carrier (8/13), Hb H disease (1/13) and homozygous α o -thalassemia (Hb Bart's hydrops fetalis; 2/13) using DNA extracted from 200 μl plasma. The α o -thalassemia was detected using a two-step PCR. Ten μl of plasma DNA was amplified conventionally using α o -thalassemia specific primers and 5 μl of the first PCR product was subjected to a semi-nested real time Q-PCR using the SYBR green I chemistry for fluorescent detection on the Rotor Gene 3000 (Corbett Research, Australia). Calibration curve for α o -thalassemia quantification was prepared by assaying serial dilution of genomic DNA of an α o -thalassemia carrier. Assay was performed in duplicate and data analysed using the Rotor Gene 6 software. Differences in the Ct values and calculated concentrations of amplified DNA among normal fetus, α o -thalassemia carrier, Hb H disease and homozygous α o -thalassemia were clearly observed which could help in prenatal prediction of the fetal genotype. The result was completely concordant with the conventional analysis of the CVS or amniotic fluid specimens. This noninvasive prenatal detection of the fetal α othalassemia should enhance prenatal diagnostic options for this common genetic disorder. Background: DNA of fetal origin is present in the plasma of pregnant women. The quantitative measurement of circulatory fetal DNA (cfDNA) by real-time quantitative PCR has been applied to investigate a possible correlation between increased levels and pregnancy-related disorders, including pregnancies with trisomy 21 fetuses or those with preeclampsia. However, as the levels of cfDNA analyzed are close to the detection limit (LOD) of the method used the measurements may not be reliable.
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Methods: We optimized a protocol for the real-time quantitative PCR amplification of the multi-copy sequence DYS14 on the Ychromosome. This was compared with an established real-time PCR assay for the single copy SRY gene.
Results: We demonstrate by probit regression analysis that the measurements of male DNA by the DYS14 assay have tenfold lower limit of detection (0.4 genome equivalents (GE)) and limit of quantification in comparison to SRY (4 GE). This is confirmed by the smaller variability in the analysis of low template genomic DNA and plasma samples of women in the first trimester of pregnancy, coefficients of variation (CV) are 2 to 22% when amplifying DYS14 compared to 26-140% for SRY.
Conclusions: The low copy numbers of fetal DNA in plasma of women in the first trimesters of pregnancy cannot be reliably measured targeting single copy sequences due to variable PCR amplification. We have addressed this problem by amplifying a sequence that is present in multiple copies per male genome. The aim of this investigation was to compare the contents of sequences hybridizing with probe directed to 28s rRNA gene, subfraction of human satellite iii or to the histone genes in DNA isolated from serum of 65 pregnant women (31 in first trimester, 34 in mid trimester) and peripheral blood leukocytes. DNA was isolated from serum or cells according to standard protocols. DNA concentration was estimated fluorimetrically with Hoechst 33258. Quantitative analysis of repeat units was performed by non-radioactive dot-hybridization, using biotinylated probes. The value R is the quotient of the quantity of DNA repeats, contained in total cell-free DNA (tcfDNA) and in cell DNA. The quantity of repeat units were different in cell DNA and tcfDNA. The median r was 4.2, 1.1 and 0.8 for the repeat units of 28S rRNA gene, histone genes and satellite iii respectively. The median R for the 28S rRNA gene in the second trimester was 1.8 times more than in the first trimester, while the median DNA concentration was 1.5 times less. Among 31 serum from first trimester pregnancies low (m=0.36MoM), normal (m=1.17MoM) and high level of hCG (m=3.38MoM) was detected in 10, 13 and 8 samples, respectively. In samples with low hCG level the r for the 28s rRNA gene was increased 1.6 times, while tcfDNA concentration was decreased 1.5-2.6 times in comparison with other samples. The R for the 28SrRNA gene can be an additional marker of apoptosis.
